Literature DB >> 10731446

Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan.

J Levijoki1, P Pollesello, J Kaivola, C Tilgmann, T Sorsa, A Annila, I Kilpeläinen, H Haikala.   

Abstract

Levosimendan, an inodilatory drug discovered using troponin C as a target protein, has a cardiac effect deriving from the calcium sensitization of contractile proteins. The aim of this study was to give further evidence that levosimendan binds to cardiac troponin C and that the binding involves amino acid residues on helixepsilon of the N-terminal domain of this calcium-binding protein. Nine organic molecules, obtained by chemical modification of levosimendan, were tested both for their calcium-dependent binding to troponin C and troponin complex affinity HPLC columns, and for their ability to increase the calcium sensitivity of myofilaments in cardiac skinned fibers. A good correlation between the calcium sensitization and the calcium-dependent binding to troponin complex (r=0.90) and to cardiac troponin C (r=0.91) for the analogs of levosimendan was shown. In addition, the effect of levosimendan on the calcium-induced conformational changes in native and point-mutated cTnC was studied. Cys84-->Ser, Asp87-->Lys and Asp88-->Ala point-mutated cTnC were shown to maintain a high affinity to calcium, but their Ca(2+)titration curves were not influenced by levosimendan as for the native protein. Finally, it was demonstrated that the NMR chemical shifts of the terminal methyl groups of Met47, Met81, and Met85 on calcium-saturated cTnC were changed after addition of levosimendan in water solution at pH 7.4. This effect was not seen when adding an analog of levosimendan, which did not bind to the troponin C affinity HPLC column and did not increase the calcium-induced tension in cardiac skinned fibers. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731446     DOI: 10.1006/jmcc.1999.1093

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

Review 1.  Interaction of cardiac troponin with cardiotonic drugs: a structural perspective.

Authors:  Monica X Li; Ian M Robertson; Brian D Sykes
Journal:  Biochem Biophys Res Commun       Date:  2007-12-26       Impact factor: 3.575

2.  The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis.

Authors:  Wanyu Wang; Xiaoshuang Zhou; Xinyang Liao; Bin Liu; Hai Yu
Journal:  J Anesth       Date:  2019-04-25       Impact factor: 2.078

Review 3.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

Review 4.  Levosimendan.

Authors:  D P Figgitt; P S Gillies; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Nitroxyl increases force development in rat cardiac muscle.

Authors:  Tieying Dai; Ye Tian; Carlo Gabriele Tocchetti; Tatsuo Katori; Anne M Murphy; David A Kass; Nazareno Paolocci; Wei Dong Gao
Journal:  J Physiol       Date:  2007-03-01       Impact factor: 5.182

6.  A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex.

Authors:  Ian M Robertson; Yin-Biao Sun; Monica X Li; Brian D Sykes
Journal:  J Mol Cell Cardiol       Date:  2010-08-27       Impact factor: 5.000

Review 7.  The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.

Authors:  Tia Sorsa; Piero Pollesello; R John Solaro
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

8.  Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction.

Authors:  Georgios Papadopoulos; Nikolaos G Baikoussis; Petros Tzimas; Stavros N Siminelakis; Menelaos Karanikolas
Journal:  J Cardiothorac Surg       Date:  2010-03-02       Impact factor: 1.637

Review 9.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex.

Authors:  Ian M Robertson; Olga K Baryshnikova; Monica X Li; Brian D Sykes
Journal:  Biochemistry       Date:  2008-06-21       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.